ReviewFrontiers in oncology2018
Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Case Report: Marjolin ulcer characterized by squamous cell carcinoma arising from chronic wounds: clinical features, diagnostic and therapeutic challenges, and insights-a report of four cases.Frontiers in medicine · 2026Article
- Long-Term Data From Patients Who Received Pembrolizumab in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.Case reports in oncological medicine · 2025Article
- Update on the Molecular Pathology of Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- circ_0001821 Contributes to the Development of Cutaneous Squamous Cell Carcinoma by Regulating MicroRNA-148a-3p/EGFR Axis and Activating Phosphatidylinositol 3-Kinase/Akt Pathway.Molecular and cellular biology · 2022Article
- NIX initiates mitochondrial fragmentation via DRP1 to drive epidermal differentiation.Cell reports · 2021Article
- Deciphering the Molecular Landscape of Cutaneous Squamous Cell Carcinoma for Better Diagnosis and Treatment.Journal of clinical medicine · 2020Review
- Nomogram for Preoperative Estimation of Orbit Invasion Risk in Periocular Squamous Cell Carcinoma.Frontiers in oncology · 2020Article
- High Hydrostatic Pressure Therapy Annihilates Squamous Cell Carcinoma in a Murine Model.BioMed research international · 2020Article
- miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN.Cellular & molecular biology letters · 2019Article
- Unraveling the ECM-Immune Cell Crosstalk in Skin Diseases.Frontiers in cell and developmental biology · 2019Review
- Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous squamous cell carcinoma (SCC) is one of the common cancers in Caucasians, accounting for 20-30% of cutaneous malignancies. The risk of metastasis is low in most patients; however, aggressive SCC is associated with very high mortality and morbidity. Although cutaneous SCC can be treated with surgical removal, radiation and chemotherapy singly or in combination, the prognosis of patients with metastatic SCC is poor. Recently, the usage of immune checkpoint blockades has come under consideration. To develop effective therapies that are less toxic than existing ones, it is crucial to achieve a detailed characterization of the molecular mechanisms that are involved in cutaneous SCC pathogenesis and to identify new drug targets. Recent studies have identified novel molecules that are associated with SCC carcinogenesis and progression. This review focuses on recent advances in molecular studies involving SCC tumor development, as well as in new therapeutics that have become available to clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.